Document is current
Any future updates will be listed below
-
Authors
Hamberg, Viggo https://orcid.org/0000-0001-9678-5348
Wallman, Johan K. https://orcid.org/0000-0002-4915-2924
Mogard, Elisabeth https://orcid.org/0000-0002-5706-203X
Lindqvist, Elisabet https://orcid.org/0000-0002-9937-6352
Olofsson, Tor https://orcid.org/0000-0002-9919-4487
Andréasson, Kristofer https://orcid.org/0000-0001-7021-2541
-
Funding
Funding for this research was provided by:
Anna-Greta Crafoords Stiftelse för Reumatologisk Forskning
Swedish Rheumatism Association
Stiftelsen Ulla och Roland Gustafssons Donationsfond
Lund University
- License Information
-
More Information
Article History
Received: 12 October 2022
Accepted: 17 December 2022
First Online: 25 December 2022
Declarations
:
: VH: none. JKW: consultant of AbbVie, Amgen, Celgene, Eli Lilly, Novartis (unrelated to the current study). EM: consultant of Novartis (unrelated to the current study). EL: none. To has performed consulting tasks for Merck Sharp and Dohme and for Eli Lilly (unrelated to the current study). KA: none.
